Verapamil hydrochloride (Synonyms:盐酸维拉帕米; (±)-Verapamil hydrochloride; CP-16533-1 hydrochloride)
目录号 : KM18602 CAS No. : 152-11-4 纯度 : 98%

Verapamil hydrochloride ((±)-Verapamil hydrochloride) 是一种钙通道 (calcium channel) 阻滞剂,是一种有效的口服活性的第一代 P 糖蛋白 (P-gp) 抑制剂。Verapamil hydrochloride 能也抑制 CYP3A4,并可用于高血压,心律不齐和心绞痛的研究。

规格 价格 是否有货 数量
500mg
In-stock
1g
In-stock
5g
In-stock
10g 询价 In-stock
50g 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research.

体外研究

The EverFluor FL Verapamil (EFV) uptake by TR-iBRB2 cells is inhibited by cationic drugs, and inhibits by verapamil in a concentration-dependent manner with an IC50 of 98.0 μM.

体内研究

Given orally Verapamil is useful for the prophylaxis of atrioventricular reentry tachycardia, and also in modulating the atrioventricular nodal response in atrial fibrillation.
Verapamil is injected i.v. into a femoral vein prior to ischemia. Verapamil (1 mg/kg) significantly decreases the incidence of ventricular arrhythmias including premature ventricular contractions (PVC), ventricular tachycardia (VT) and ventricular fibrillation (VF) for 45-min coronary artery occlusion. Total arrhythmia scores are significantly increased when the heart is subjected to ischemia. Verapamil (1 mg/kg) significantly prevents the enhancement of total arrhythmia scores induced by ischemia.

分子式
C27H39ClN2O4
分子量
491.06
CAS号
152-11-4
中文名称
盐酸维拉帕米;戊脉安
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

H2O : 50 mg/mL (101.82 mM; Need ultrasonic)

DMSO : 58.33 mg/mL (118.78 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0364 mL 10.1821 mL 20.3641 mL
5 mM 0.4073 mL 2.0364 mL 4.0728 mL
10 mM 0.2036 mL 1.0182 mL 2.0364 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO  →  90% saline

    Solubility: ≥ 5 mg/mL (10.18 mM); Clear solution

     

  • 2.

    请依序添加每种溶剂: 10% DMSO   → 40% PEG300   → 5% Tween-80  →  45% saline

    Solubility: ≥ 5 mg/mL (10.18 mM); Clear solution

    此⽅案可获得 ≥ 5 mg/mL (10.18 mM,饱和度未知) 的澄清溶液。

    以 1 mL ⼯作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加⼊ 50 μ L Tween-80,混合均匀;然后继续加⼊ 450 μL ⽣理盐⽔定容⾄ 1 mL。

     
  • 3.

    请依序添加每种溶剂: 10% DMSO  →  90% (20% SBE-β-CD in saline)

    Solubility: ≥ 5 mg/mL (10.18 mM); Clear solution

    此⽅案可获得 ≥ 5 mg/mL (10.18 mM,饱和度未知) 的澄清溶液。

    以 1 mL ⼯作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中,混合均 匀。

     
  • 4.

    请依序添加每种溶剂: 10% DMSO  →  90% corn oil

    Solubility: ≥ 5 mg/mL (10.18 mM); Clear solution

    此⽅案可获得 ≥ 5 mg/mL (10.18 mM,饱和度未知) 的澄清溶液,此⽅案不适⽤于实验周期在半个⽉以上的实验。

    以 1 mL ⼯作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL ⽟⽶油中,混合均匀。

临床试验
科研文献
暂无相关参考文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2